Provinces (Two-Letter Abbreviation)
= No information
= Product not available
= Covered
= Possible Private Coverage
= Conditional public Coverage
(Touch box for more details)
Metformin
Glucophage®
500 mg - 850 mg
OD to TID
Maximum daily dose: 2550 mg
Coverage
- Characteristics and clinical considerations
Metformin ER
Glumetza®
500 mg - 1000 mg
OD
Maximum daily dose: 2000 mg
Coverage
- Characteristics and clinical considerations
Acarbose
GlucobayTM
50 mg - 100 mg
OD to TID
Maximum daily dose: 300 mg
How to initiate
Coverage
- Characteristics and clinical considerations
Alogliptin
Nesina®
6.25 mg - 12.5 mg - 25 mg
OD
Coverage
QC
- Characteristics and clinical considerations
Alogliptin and Metformin
KazanoTM
12.5 mg/500 mg - 12.5 mg/850 mg - 12.5 mg/1000 mg
BID
Coverage
QC
- Characteristics and clinical considerations
Canaglifozin
Invokana®
100 mg - 300 mg
OD
Coverage
AB
MB
NB
NL
NS
PE
QC
SK
- Cardio-renal protection clinical data
- Characteristics and clinical considerations
Canaglifozin and Metformin
Invokamet®
50 mg/500 mg - 50 mg/1000 mg - 150 mg/500 mg - 150 mg/1000 mg
BID
Coverage
MB
PE
- Cardio-renal protection clinical data
- Characteristics and clinical considerations
Dapagliflozin
Forxiga®
5 mg - 10 mg
OD
Coverage
AB
MB
NB
NL
NS
PE
QC
SK
- Cardio-renal protection clinical data
- Characteristics and clinical considerations
Dapagliflozin and Metformin
Xigduo®
5 mg/850 mg - 5 mg/1000 mg
BID
Coverage
AB
MB
NB
NL
NS
PE
QC
SK
- Cardio-renal protection clinical data
- Characteristics and clinical considerations
Empagliflozin and Linagliptin
Glyxambi®
10 mg/5 mg - 25 mg/5 mg
OD
Coverage
- Cardio-renal protection clinical data
- Characteristics and clinical considerations
Empagliflozin and Metformin
SynjardyTM
5 mg/500 mg - 5/850 mg - 5 mg/1000 mg - 12.5 mg/500 mg - 12.5 mg/850 mg - 12.5 mg/1000 mg
BID
Coverage
BC
NB
NS
PE
QC
SK
- Cardio-renal protection clinical data
- Characteristics and clinical considerations
Gliclazide
Diamicron®
80 mg
OD to BID
Maximum daily dose: 320 mg
Coverage
BC
- Characteristics and clinical considerations
Gliclazide Modified Release
Diamicron®MR
30 mg - 60 mg
OD
Maximum daily dose: 120 mg
Coverage
BC
- Characteristics and clinical considerations
Glimepiride
Amaryl®
1 mg - 2 mg - 4 mg
OD to BID
Maximum daily dose: 8 mg
Coverage
MB
ON
QC
- Characteristics and clinical considerations
Glyburide
Diabeta®
2.5 mg - 5 mg
OD to BID
Maximum daily dose: 20 mg
Coverage
- Characteristics and clinical considerations
Repaglinide
GlucoNorm®
0.5 mg - 1 mg - 2 mg
OD to TID AC
Maximum daily dose: 16 mg
Coverage
MB
NL
ON
SK
- Characteristics and clinical considerations
Rosiglitazone
Avandia®
2 mg - 4 mg - 8 mg
OD
Coverage
AB
ON
QC
SK
- Characteristics and clinical considerations
Dulaglutide
Trulicity®
0.75 mg - 1.5 mg
Once-Weekly
Stability at room temperature : 14 days
Coverage
QC
- Characteristics and clinical considerations
- Cardio-renal protection clinical data
Instructions for Use Video
Exenatide
Byetta®
5 µg - 10 µg
BID (60 min AC)
Stability at room temperature : 30 days
Coverage
- Cardio-renal protection clinical data
- Characteristics and clinical considerations
Exenatide Sustained Release
Bydureon®
2 mg
Once-Weekly
Stability at room temperature : 4 weeks
Coverage
- Cardio-renal protection clinical data
- Characteristics and clinical considerations
Liraglutide
Victoza®
0.6 mg - 1.2 mg - 1.8 mg
OD
Stability at room temperature : 30 days
Coverage
QC
- Cardio-renal protection clinical data
- Characteristics and clinical considerations
Video demo. of the injection technic
Lixisenatide
AdlyxineTM
10 ug/dose (0.05 mg/ml)
20 ug/dose (0.1 mg/ml)
OD
Stability at room temperature : 14 days
Coverage
- Cardio-renal protection clinical data
- Characteristics and clinical considerations
Semaglutide (s/c)
Ozempic®
0.25 mg - 0.5 mg - 1 mg
Once-Weekly
Stability at room temperature : 8 weeks
Coverage
AB
NB
NL
NS
PE
QC
SK
- My Treatment Guide
- Cardio-renal protection clinical data
- Characteristics and clinical considerations
Video demo. of the injection technic (8 Languages)
Semaglutide (oral)
Rybelsus®
3 mg - 7 mg - 14 mg
OD
Private coverage
- Patient Guide
- Getting Started
- Cardio-renal protection clinical data
- Characteristics and clinical considerations
Glargine U100 (100 units/ml) / Lixisenatide (33 mcg/ml)
SoliquaTM
Maximum recommended daily dose is 60 units:
Glargine U100 60 units / Lixisenatide 20 mcg
How to Inject (video)
How to Inject
Therapy Initiation and Titration
- Cardio-renal protection clinical data
- Characteristics and clinical considerations
Degludec (100 units/ml) / Liraglutide (3.6 mg/ml)
Xultophy®
Maximum recommended daily dose is 50 units:
Degludec 50 units / Liraglutide 1.8 mg
Therapy Initiation and Titration
Coverage
- Cardio-renal protection clinical data
- Characteristics and clinical considerations